Top Story

First-line pembrolizumab superior to ipilimumab for advanced melanoma

First-line pembrolizumab superior to ipilimumab for advanced melanoma
April 19, 2015

Read the Perspective from Suzanne L. Topalian, MD

PHILADELPHIA — Patients with advanced melanoma who received first-line pembrolizumab achieved significantly prolonged OS and PFS compared with patients who received ipilimumab, according to phase 3 study results presented at the American Association for Cancer Research Annual Meeting.

These results represent the first randomized comparison of two FDA-approved immune checkpoint inhibitors for the first-line treatment of advanced melanoma, according to the researchers.

Edward Garon Meeting News CoveragePerspective

PD-L1 expression linked to pembrolizumab activity in advanced NSCLC

April 19, 2015
PHILADELPHIA — Pembrolizumab yielded durable response rates and demonstrated tolerability in previously treated and treatment-naive patients with non–small…
Meeting News Coverage

SLNB used in patients with thin melanomas prior to guidelines

April 18, 2015
NEW YORK — Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph…
Meeting News Coverage

HD IL-2 extends OS in malignant melanoma

April 18, 2015
NEW YORK — Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according…
More News Headlines »
Cover Story Publication Exclusive
Maintaining public awareness is critical to solving the problem of drug shortages, according to J. Leonard Lichtenfeld, MD, MACP, deputy chief medical officer for the American Cancer Society. “If we don’t constantly revisit this and make people aware of it, then this will become the status quo,” he said.

Expectation of drug shortages has become ‘new norm’ for cancer care

HemOnc Today, February 10, 2015
More than 230 drugs appeared on the American Society of Health-System Pharmacists’ drug shortage list as of…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
morganatic-roan
morganatic-roan